Can inhaled nintedanib improve tolerability and adherence in IPF treatment, according to Avalyn Pharma Inc.?
Read More 3 minute read Pharma Industry News Everest Medicines’ EVER001 shows promising Phase 1b/2a trial results for autoimmune kidney disease treatment Everest Medicines has announced promising preliminary results from its ongoing Phase 1b/2a clinical trial of EVER001, a next-generation… byPallavi MadhirajuDecember 4, 2024